CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL) (CD19TPALL)
Immunotherapy With CD19ζ Gene-modified EBV-specific CTLs After Stem Cell Transplant in Children With High-risk Acute Lymphoblastic Leukaemia
Sponsor: Children with Leukaemia
Terminated
Due to lack of biological efficacy and CD19 CAR CTL persistence
Other Acute Lymphoblastic Leukemia trials with similar outcome
A PHASE1/PHASE2 clinical study on Acute Lymphoblastic Leukemia, this trial is terminated or withdrawn. The trial is conducted by Children with Leukaemia and has accumulated 7 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
▶ Show 2 earlier versions
-
Apr 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Apr 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
May 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Children with Leukaemia
- Department of Health, United Kingdom
- Deutsche Krebshilfe e.V., Bonn (Germany)
- European Union
- JP Moulton Charitable Foundation
- The Leukemia and Lymphoma Society
- University College, London
For direct contact, visit the study record on ClinicalTrials.gov .